
## Shilpa S Tummala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8794568/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomas. Oncotarget, 2017, 8, 109228-109237.	1.8	89
2	Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. Journal of Neuro-Oncology, 2019, 141, 327-335.	2.9	72
3	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathologica, 2018, 136, 779-792.	7.7	66
4	Genotype-targeted local therapy of glioma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8388-E8394.	7.1	40
5	Accelerated progression of IDH mutant glioma after first recurrence. Neuro-Oncology, 2019, 21, 669-677.	1.2	38
6	A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. Neurosurgery, 2019, 85, 204-210.	1.1	28
7	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clinical Cancer Research, 2019, 25, 4375-4387.	7.0	26
8	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. Cancer Research, 2020, 80, 5330-5343.	0.9	19
9	TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Acta Neuropathologica Communications, 2018, 6, 106.	5.2	18
10	Sirtuin activation targets IDH-mutant tumors. Neuro-Oncology, 2021, 23, 53-62.	1.2	15
11	SURG-05MOLECULAR CORRELATES OF TUMOR SIZE AND MRI CONTRAST ENHANCEMENT IN A COHORT OF LOWER-GRADE GLIOMA PATIENTS. Neuro-Oncology, 2015, 17, v215.1-v215.	1.2	0
12	151 TERT Promoter Mutations in Progressive Treatment-resistant Meningiomas. Neurosurgery, 2017, 64, 236-237.	1.1	0
13	NIMG-62. RADIOLOGIC RESPONSE RATE OF IDH MUTANT GLIOMA FOLLOWING RADIATION TREATMENT: AÂRETROSPECTIVE ANALYSIS. Neuro-Oncology, 2017, 19, vi156-vi156.	1.2	0
14	MNGI-37. DMD GENOMIC DELETIONS CHARACTERIZE A SUBSET OF PROGRESSIVE/HIGHER-GRADE MENINGIOMAS WITH POOR OUTCOME. Neuro-Oncology, 2018, 20, vi157-vi157.	1.2	0